Malaria vaccine - Apovia

Drug Profile

Malaria vaccine - Apovia

Alternative Names: ICC 1132; MalariVax™

Latest Information Update: 22 Nov 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Apovia (CEASED)
  • Developer Malaria Vaccine Initiative
  • Class Parasitic vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Malaria

Most Recent Events

  • 18 Feb 2005 A clinical study has been added to the Parasitic infections immunogenicity section
  • 16 Dec 2003 Data presented at the 52nd Annual Meeting of the American Society of Tropical Medicine and Hygiene (ASTMH-2003) have been added to the Parasitic Infections immunogenicity section
  • 03 Dec 2003 A phase I trial has been completed for Malaria in Germany
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top